Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 1/20 | 0.56 |
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.53 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.52 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234324 | 1.00 | SELP (0.56) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL28662590 | 1.00 | SELP (0.56) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL25351937 | 1.00 | SELP (0.56) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL1296327 | 0.99 | SELP (0.57) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL1296508 | 0.99 | SELP (0.57) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL1295804 | 0.99 | SELP (0.57) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL1295566 | 0.99 | SELP (0.57) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL1296243 | 0.93 | SELP (0.65) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL235778 | 0.93 | PLA2G2C (0.48) | SELPFABP3ENPP2P2RY10GPR34 | |
| SCHEMBL30976336 | 0.93 | PLA2G2C (0.48) | SELPFABP3ENPP2P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458083-B1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX INC (US) | 2022-11-02 | — | — | EP | claimed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4637812-A1 | HEPATITIS B COMPOSITIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152737-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4539876-A2 | RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 | GlaxoSmithKline Biologicals S.A. (BE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250099576-A1 | Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2 | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-03-27 | — | — | US | disclosed |
| EP-2578237-A1 | Compositions and methods for enhancing contrast in imaging | Marval Biosciences, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120301457-A1 | LIPID COFACTORS FOR FACILITATING PROPOGATION OF PRPsc | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2012-11-29 | — | — | US | disclosed |
| EP-2410990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | Marval Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120003159-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010107990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | MARVAL BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7785568-B2 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL BIOSCIENCES, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080131369-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVEL THERAPEUTICS (US) | 2008-06-05 | — | — | US | disclosed |
| US-20070212303-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL PHARMA, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099576-A1 | Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2 | RNGTT, RBM25, TMPRSS2 | SELP 2589/4885FABP3 243/4885ENPP2 2437/4885 |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT5B | SELP 1722/4885FABP3 218/4885ENPP2 205/4885 |
| US-20120301457-A1 | LIPID COFACTORS FOR FACILITATING PROPOGATION OF PRPsc | PRNP, PRPH, PRPS1 | SELP 235/4885FABP3 1187/4885ENPP2 511/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | SELP 901/4885FABP3 195/4885ENPP2 1409/4885 |
| US-20250152737-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | HDLBP, LIPC, LIPG | SELP 328/4885FABP3 2175/4885ENPP2 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.